3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
11
Lymphoma
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Neoplasm Metastasis
9
Leukemia
9
Neoplasms
8
Myelodysplastic Syndromes
8
Hodgkin Disease
8
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
8
Lymphoma, Non-Hodgkin
7
Leukemia, Myeloid, Acute
7
Carcinoma, Renal Cell
7
Prostatic Neoplasms
6
Melanoma
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Recurrence
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Hematologic Neoplasms
5
Graft vs Host Disease
5
Advanced Cancer
5
Unspecified Adult Solid Tumor, Protocol Specific
4
Primary Myelofibrosis
4
Pancreatic Neoplasms
4
Neoplasms, Plasma Cell
4
Myeloproliferative Disorders
4
Lung Neoplasms
4
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Myeloid, Chronic-Phase
4
Glioblastoma
4
Interventions
venetoclax
6
Azacitidine
6
Cytarabine
5
fludarabine
4
Methotrexate
3
fludarabine phosphate
2
aldesleukin
2
RO6839921
2
Mitoxantrone
2
Interleukin-2
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Decitabine
2
Dasatinib
2
zileuton
1
thymoglobulin
1
spartalizumab
1
sabatolimab
1
quizartinib
1
pulrodemstat besilate
1
posaconazole
1
plerixafor
1
gilteritinib
1
etoposide phosphate
1
emvododstat
1
daratumumab
1
blinatumomab
1
Sorafenib
1
Sirolimus
1
Panobinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Leukemia, Myeloid
×
Sirolimus
×
Clear all
NCT00780104
2019-07-12
UPCC 02407
Abramson Cancer Center at Penn Medicine
Phase 1
Completed
16 enrolled